De Rycker, Manu, Horn, David, Aldridge, Bree, Amewu, Richard K, Barry, Clifton E, Buckner, Frederick S, Cook, Sarah, Ferguson, Michael A J, Gobeau, Nathalie, Herrmann, Jennifer, Herrling, Paul, Hope, William, Keiser, Jennifer, Lafuente-Monasterio, Maria Jose, Leeson, Paul D, Leroy, Didier, Manjunatha, Ujjini H, McCarthy, James, Miles, Timothy J, Mizrahi, Valerie, Moshynets, Olena, Niles, Jacquin, Overington, John P, Pottage, John, Rao, Srinivasa P S, Read, Kevin D, Ribeiro, Isabela, Silver, Lynn L, Southern, Jen, Spangenberg, Thomas, Sundar, Shyam, Taylor, Caitlin, Van Voorhis, Wes, White, Nicholas J, Wyllie, Susan, Wyatt, Paul G, Gilbert, Ian H.
In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.